Seeking Alpha

Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized

LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc (AGEN). (Nasdaq: AGEN) today reported financial results for the fourth quarter and full year ended December 31, 2025, highlighting progress for the ...
Business Wire

Agenus Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a pioneer in immuno-oncology, today announced a strategic initiative to prioritize and focus resources to accelerate the ...
Dark Reading

DataDome Expands Bot Bounty Program to the Public, Invites Researchers to Rigorously Test its Solution

NEW YORK, Feb. 13, 2024 /PRNewswire/ -- DataDome, a leading provider of AI-powered online fraud and bot management, today announced it has opened its bot bounty program to the public, in partnership ...
AFP

Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, and BAP Pharma, a global medicines access and clinical trial supply company, today announced the exclusive appointment of BAP Pharma ...